Knowledge Hub
Knowledge Hub
After six years as CEO, Siobhan Conroy stepped down from the Unicorn Foundation NZ board, leaving behind a transformed landscape for NET patients.
After six years as CEO, Siobhan Conroy stepped down from the Unicorn Foundation NZ board in December 2021.
As CEO for six years, she made huge advances for neuroendocrine cancer patients in New Zealand — from establishing a national patient support network, to championing access to Gallium-68 imaging, to laying the groundwork for the introduction of PRRT.
Specialist diagnostic scans identify if a NET cancer patient is a suitable candidate for PRRT — a treatment pathway that wouldn't have been possible in Aotearoa without Siobhan's persistent advocacy.
Honouring a legacy: Malcolm Legget MNZM
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
Waikato clinicians publish rare renal NET case in international oncology journal
A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging
Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
Lanreotide now funded in New Zealand for neuroendocrine tumours
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.